129
Participants
Start Date
November 30, 2006
Primary Completion Date
July 31, 2011
Study Completion Date
July 31, 2011
Mycobacterial cell wall-DNA complex
8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
Memorial Sloan Kettering Cancer Centre, New York
Hudson Valley Urology, Poughkeepsie
University of Rochester Medical Center, Rochester
Triangle Urology Group, Pittsburgh
Chesapeake Urology Research Associates, Towson
Johns Hopkins University, Baltimore
Sentara Medical Group - Urology of Virginia, PC, Norfolk
Winter Park Urology Associates P.A., Orlando
University of Miami School of Medicine, Miami
Vanderbilt University Medical Center, Nashville
Welborn Clinic, Evansville
The University of Chicago Hospitals, Chicago
Urology Clinics of North Texas, P.A., Dallas
M.D. Anderson Cancer Center, Houston
Urology San Antonio Research, PA, San Antonio
BCG Oncology, Phoenix
Sheldon J Freedman, MD, Ltd, Las Vegas
San Diego Clinical Trials, San Diego
Connecticut Urological Research at Grove Hill, New Britain
Delaware Valley Urology, LLC-Voorhees, Voorhees Township
Andreou Research, Surrey
Can-Med Clinical Research, Victoria
Dr. Steinhoff Clinical Research, Victoria
Centre for Applied Urological Research, Kingston
London Health Sciences Centre, London
Sunnybrook Health Sciences Centre, Toronto
University Health Network / Princess Margaret Hospital, Toronto
The Male Health Center, Toronto
Centre Hospitalier de l'Universite de Montreal, Montreal
Jewish General Hospital, Montreal
Centre de Recherche du CHUQ, Québec
Lead Sponsor
Bioniche Life Sciences Inc.
INDUSTRY